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Biologics-based therapeutics have witnessed remarkable market growth in the past couple 
of decades with continuing future potential. Expiring patents on tried-and-true monoclonal 
antibody (mAb) drugs put tremendous pressure on pharmaceutical manufacturing compa-
nies to develop biosimilars as quickly and efficiently as possible. One of the biggest bot-
tlenecks in the scale-up of biopharmaceuticals manufacturing is the production of biomol-
ecules, and this is largely a consequence of cell culture constraints. Robust mammalian cell 
lines, such as Chinese hamster ovary (CHO) or non-secreting myeloma (NS0) cells, have 
been extensively characterized using -omics technologies; however, there is still more re-
search to be done. One of the most high-impact changes that a pharmaceutical development 
company can make is the optimization of their cultures, and one of the best ways to do this 
is through the optimization of media composition and feeding strategy (for fed-batch cul-
tures). Since basal media is often generalized for many cell lines of a particular cell type, 
supplementations must be made to cater to the specific nutrient requirements for the clone 
being cultured and biologic being produced. These needs are determined by collecting data 
on the consumption and production of nutrients and metabolites in the culture media and 
within the cells. The aim of this project is to culture mAb-producing GS-CHO cells and 
characterize their metabolic needs and behavior using quantitative methods such as high-
performance liquid chromatography (for amino acids, vitamins, and mAb titer), flow cy-
tometry (for cell count and viability), fluorescence measurements (for ATP) and BioPro-
filing (for glucose, lactate, and inorganic salts). It can be difficult to draw conclusions from 
so many data, so a streamlined and automated platform for multivariate analysis using 
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Excel and R programming allows for clearer visualization of the data at a high level using 
techniques like hierarchical clustering and principal component analysis. This analysis 
helps elucidate relationships and shifts between the variables, which can be used to im-
prove upon future cultures by informing model-based optimization software and providing 
a better understanding of specific culture needs.







Bioprocess optimization can be a daunting task due to its complex and costly nature, and 
for these reasons, many biopharmaceutical companies avoid spending too much time or 
money on it. Inefficient batch processes still dominate the market, despite theoretically 
superior alternatives and optimization opportunities [1]. Given the multitude of process 
parameters that must be considered at each stage of the manufacturing process, this is 
somewhat understandable. Below is a fishbone diagram recreated from a case study con-
ducted by some of the leading global biopharmaceutical development companies, which 




Figure 1.1: Process Parameters for Cell Culture in Biopharmaceutical Manufacturing [2] 
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The existence of so many process parameters makes it challenging to isolate which ones 
might be the most impactful when optimized. One strategy to determine the ideal factor 
conditions and how they influence one another is to employ design of experiments (DOE). 
This is an optimization strategy that uses applied statistics to generate an array of different 
experimental conditions that result in the comprehensive testing of multiple process pa-
rameters in a highly controlled manner. This systematically evaluates each parameter and 
its impact on the process responses (such as yield or cell density) to maximize productivity 
and minimize variability [3]. A technique known as factorial design is used to determine 
which factors (synonymous to independent variables) are to be varied during experimental 
runs and how many levels will be tested (low, medium, high, etc.). While DOE-based op-
timization is successful by design, it often requires that hundreds of runs be conducted, 
many of which may not be very successful, which is costly in terms of time and resources. 
For example, using Figure 1.1 as a reference, if even just two levels were to be tested for 
each of the thirteen factors listed under the production bioreactor process, 8,192 runs would 
be required to test every combination of levels. Such excessive testing is clearly unrealistic, 
and there are techniques to decrease the number of required runs given limited resources - 
such as selectively testing for specific relationships and not others, or choosing to omit the 
investigation of certain factors or levels entirely based on existing information – but it is 
easy to imagine how this strategy can be difficult to apply to multi-step industrial biopro-
cesses [3]. However, this trial-and-error based optimization is one of the most widely uti-
lized techniques by companies, due to its straightforwardness, simplicity and barriers to 
entry for superior alternatives.  
        The aim of this thesis is to design a multivariate data analysis platform to inform 
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bioprocess optimization, with a focus on chemically defined media composition. While 
there are many offerings on the market for tried-and-true culture media formulations for 
popular mammalian cell lines, genetic variation between cell line clones and differing 
chemical compositions between biologics demands specific nutrient requirements which 
may not be met by generalized culture media formulations [4]. Therefore, this project seeks 
to profile the metabolic behavior of an industrially relevant mammalian cell line producing 
a monoclonal antibody by extensively analyzing batch cultures. More specifically, quanti-
tative lab techniques will be used to determine the dynamic concentrations of amino acids, 
vitamins, metabolites and monoclonal antibody product in spent media samples (collected 
daily) and develop a streamlined analysis platform to draw conclusions about the cellular 
metabolism and productivity over time in order to inform a media design-based optimiza-
tion strategy. This is beneficial because the ability to identify patterns and correlations in a 
large set of data from a single experiment could significantly reduce the number of further 
experiments required for optimization by pinpointing potential key nutrients to focus on 
for supplementation.







2.1 What are Monoclonal Antibodies? 
Monoclonal antibodies (mAbs) have reshaped the biologics and targeted therapeutics mar-
kets since their advent just a few decades ago, and continual improvements in their devel-
opment yield a promising future [5]. In short, monoclonal antibodies are immunoglobulin 
G (IgG) proteins secreted by white blood cells that selectively target a single antigen 
epitope with high specificity. Their incorporation in drug formulations allows for the tar-
geted treatment of a specific disease, greatly reducing side effects and enhancing efficacy. 
The industrial production of therapeutic mAbs has experienced remarkable growth expan-
sion, having reached a market size of $98 billion in 2017, excluding diagnostic and aca-
demic applications [5]. This chapter will provide a brief overview of their historical dis-
covery and characterization, discuss current and future improvements to developmental 
and manufacturing practices, and explain their diverse applications and clinical relevance. 
Portions of this chapter are from a forthcoming chapter by myself, Dr. Ana Quiroga and 
Dr. Sakis Mantalaris in A Handbook of Molecular Biotechnology, entitled “Monoclonal 
Antibodies”. 
 
2.1.1 Monoclonal Antibody Structure 
Monoclonal antibodies are Y-shaped glycoproteins, and they can be segmented into two 
regions: the antigen binding fragments (Fab) which make up the two branches of the “Y”, 
and the crystallizable fragment which forms the body of the “Y”. The antigen-binding 
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fragments can be further segmented into their light and heavy chains [6]. Heavy chains 
have a molecular weight of 50-70 kDa and span the entire length of the antibody molecule 
[7]. Possessing 4-5 total domains, the heavy chains contain one variable domain (VH) 
located within the Fab, and the remaining conserved domains (CH) reside in the Fc region. 
The light chains, in contrast, weigh only 25 kDa and are found exclusively within the 
antigen-binding fragments [7]. Each light chain possesses one variable domain (VL) and 
once conserved domain (CL). Disulfide bonds connect the light and heavy chains within 
the Fabs, and also connect the two heavy chains in the Fc region. The maintenance of these 
disulfide bonds is critical to the structural and functional integrity of mAbs, so they are 
considered a critical quality attribute (CQA) of the final pharmaceutical product [8]. All of 
these structures are collectively depicted in Figure 2.1. 
 
 
Figure 2.1: Monoclonal Antibody Structure (created with Biorender.com) [6] 
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2.1.2 Antibody Fragments 
Given their larger size, mAbs can be fragmented in numerous different ways to preserve 
functionality in smaller form factors. These fragments can be engineered to either function 
independently or can be incorporated into pharmaceutical formulations or delivery 
methods (such as conjugation to nanoparticles) for targeted therapies. Monoclonal 
antibody fragments can be broadly categorized as either “true” or “engineered”. True 
fragments describe any type of fragmentation that preserves its structural integrity from the 
original whole IgG molecule, whereas engineered fragments involve a combination or 
structural rearrangement of true fragments to make up an entirely new structure which is 
not represented in the whole molecule. Common examples of both types of fragments are 
visualized in Figure 2.2. 
 
 
Figure 2.2: Antibody Fragments (created using BioRender.com) [9] 
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2.1.3 IgG Antibody Glycosylation 
Glycosylation, another critical quality attribute of mAbs, describes one of the post-
translational modifications to the constant region and is a very important factor in the 
efficacy and safety of therapeutic mAbs. In short, complex structures of glycosidically-
linked monosaccharides (glycans) are joined to either side of the FC region of an IgG 
antibody after its production, and these glycans must be accurately and consistently 
reproduced in cultures to maintain the effectiveness and homogeneity of a mAb product. 
Glycosylation employs complex multi-step biochemical pathways that have been 
extensively characterized, but the functional purposes of glycosylation are not yet fully 
understood. It is known that glycosylation in the rough ER serves as a labelling mechanism 
to identify proper protein folding and also significantly impacts protein-protein interactions 
by physically modifying the structure of mAbs, preventing unfavorable binding and/or 
facilitating necessary binding. Glycosylation aides in communication with receptors in the 
Golgi network which is responsible for facilitating their secretion. The main types of 
glycosylation are defined by their site of linkage on the Fc region of the mAb: N-linked 
glycosylation, by far the most common type, involves the binding of the glycan to the 
amino group of an asparagine residue. O-linked glycosylation entails linkage to the 
hydroxyl group of a threonine or serine residue and describes approximately 10% of 
glycosylation patterns. The specific structural composition of a given glycan to a mAb is 
termed a glycoform, and robust bioprocessing aims to avoid glycoform heterogeneity in 
the product. A summary of common glycosylation steps and incorporated sugars (such as 
galactose, mannose and fucose) is given in Figure 2.3. 
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Figure 2.3: IgG Antibody Glycosylation (created using BioRender.com) [10] 
 
2.1.4 Bispecific IgG Antibodies 
Monoclonal IgG antibodies, which are innately monospecific, can be engineered to be 
alternatively “bispecific”. As previously described, IgG antibodies have two antigen 
binding sites, and this pair of Fabs is naturally identical. However, the substitution of an 
Fab with one derived from a different mAb results in an antibody that yields specific 
binding to two epitopes of an antigen, or even two separate antigens entirely (Figure 2.4). 
Monoclonal antibodies that possess heterogenous binding sites are advantageous in 
situational applications, which will be described in greater detail in a later section. 
 
 
Figure 2.4: Bispecific IgG Antibody (created using BioRender.com) 
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2.1.5 Humanization of Monoclonal Antibodies 
Since monoclonal antibodies are conventionally produced by murine cells, they naturally 
invoke an unwanted immunogenic response when administered in humans. This is because 
murine genomes possess enough differences from the human genome that the mAbs 
produced fundamentally lack the same post-translational modifications found in proteins 
endogenously produced in humans. Therefore, initial mAb therapies were flagged as 
foreign molecules by patient immune systems and neutralized before they could effectively 
enact their therapeutic action, making them largely unsuccessful. In general, they also 
yielded lower affinity and cytotoxicity than desired. This prompted immediate efforts to 
“humanize” mAbs and approve efficacy, of which there are multiple approaches (Figure 
2.5). 
        Chimerization of mAbs involves the combination of structural components 
genetically derived from humans and rodents. More specifically, the variable domains of 
murine mAbs are combined with the constant region of a human IgG antibody, resulting in 
a mAb that is genetically 65%-75% human whilst maintaining the specific antigen binding 
fragments produced by murine hybridomas. Abciximab, a cardiovascular disease therapy 
targeting the GPIIb/IIIa complex on platelets to prevent aggregation, received FDA 
approval in 1994 and was the first medication to implement chimeric antibodies [11]. 
Humanized antibodies are conceptually similar but incorporate an even smaller fragment 
of murine mAbs. Instead of incorporating the entire variable domain into a human IgG 
antibody, only the hypervariable sequences responsible specifically for antigen binding are 
grafted, resulting in a mAb that is genetically more than 90% human. The first humanized 
mAb to receive FDA approval was Daclizumab which targeted the IL-2 receptor for 
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prevention of transplant rejection [11]. The production of fully human mAbs can be 
obtained using transgenic mice hybridomas or phage display technology, which will be 
described in the following section. Adalimumab, an immunosuppressant primarily for the 
treatment of rheumatoid arthritis, received FDA approval in 2002 and was the first fully 
human mAb on the market. Developed by AbbVie under the brand name Humira, it 
achieved huge success and was the bestselling mAb therapeutic in 2018 [11]. The level of 
humanization for a clinically approved mAb can be discerned by its suffix nomenclature: 
“-omab” describes fully murine mAbs, “-ximab” describes chimeric mAbs, “-zumab” 
describes humanized mAbs, and “-umab” describes fully human mAbs. 
 
 
Figure 2.5: Humanization of Monoclonal Antibodies (created using BioRender.com)  
 
2.2 Antibody Discovery 
Antibodies found in blood serum are heterogeneous, meaning that they are composed of a 
polyclonal mixture that recognizes different epitopes of the same antigens and also 
different antigens entirely. Because B-cells are only capable of recognizing and secreting 
antibodies for a single epitope of a single antigen, there exists vast heterogeneity within a 
single person or animal’s population of B-cells to provide immunity against a diverse range 
of diseases. This diversity is made possible by the processes described in 1957 by 
immunologists Frank Burnet and David Talmage in their “clonal selection theory” [12]. 
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They hypothesized that hematopoietic stem cells (HSCs) differentiate into immature B 
lymphocytes that possess their own unique antigen receptor. Of these cells, those that yield 
specificity to antigens presented by endogenous cells are destroyed to prevent 
autoimmunity. Those who are incapable of spontaneously forming bonds with endogenous 
tissues further differentiate into mature, inactive lymphocytes. These cells circulate 
throughout the bloodstream until they encounter a foreign antigen that stimulates an 
intracellular signaling pathway to promote antibody production and cell division, creating 
many clones that can produce the same antibody [12].  
        Activated B lymphocytes can either mature into memory B cells, which exist in a 
quiescent state until they once again encounter their activating antigen (serving as a 
“memory” for the immune system), or plasma B cells which actively produce and secrete 
large volumes of antibody. The production of mAbs relies on the isolation and subsequent 
expansion of a single plasma B cell; unfortunately, primary B-cells cannot reach high cell 
densities and can only divide a finite number of times, making them incompatible 
candidates for swift and large-scale production of mAbs [13]. The revolutionary invention 
of hybridoma technology by Georges Kohler and Cesar Milstein in 1975 addressed this 
problem and paved the way for the industrial production of mAbs seen today [14]. 
 
2.3 Early Development: Hybridoma Technology 
Hybridoma technology is a conceptually simple process of fusing plasma B cells with 
immortal myeloma cells, creating “hybridoma” cells. These cells possess the antibody-
secreting capabilities of the plasma B cells while adopting the immortality and high 
proliferation of the cancer cells. This technique can be segmented into six main steps: first, 
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a mouse is injected with a specific antigen to invoke its adaptive immune response. This 
antigen is typically a key biomarker for a disease of interest that researchers are attempting 
to develop a targeted therapy for. After allowing infection to occur, spleen tissue is 
harvested from the mouse and the antibody-secreting B cells are subsequently isolated. 
Next, the harvested B cells must be fused with myeloma cells to generate hybridoma cells. 
Successfully fused cells must then be selected for by culturing in hypoxanthine-
aminopterin-thymidine medium (HAT) medium.  
 
 
Figure 2.6: Hybridoma Technology (created using BioRender.com) [15] 
 
This selection technique functions based on two key principles: unfused B cells from the 
spleen will not replicate in culture, and unfused myeloma cells are actively selected against 
by HAT in the medium. HAT blocks the DNA de novo nucleotide synthesis pathway, 
ultimately preventing DNA replication from proceeding; therefore, the only cells that will 
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survive are properly fused hybridoma cells. Next, hybridomas that selectively bind to the 
injected antigen are screened for using an antigen-presenting affinity assay (such as 
ELISA). Once the preferred clones are selected, they can be independently expanded in 
culture for the eventual harvest of their antibodies. All described steps are visualized in 
figure 2.6. The first FDA approved monoclonal antibody produced by this technology was 
Orthoclone OKT3 (generically known as muronomab-CD3), an immunosuppressant 
targeting the CD3 receptor developed by Janssen-Cilag in 1986 [16]. 
 
2.4 Principles of Monoclonal Antibody Production 
Before mAbs can be manufactured at large, high affinity clones capable of neutralizing a 
specific disease epitope must first be isolated from B cells. This requires the sorting and 
screening of individual B cells from a population (such as spleen tissue or a PBMC patient 
sample), as described in the discussion of hybridoma technology. There are multiple 
existing techniques for clonal selection, with great potential for the development of novel 
methods and technologies. This is a critical step of the mAb manufacturing process because 
the efficacy of mAb therapeutics hinges significantly on the affinity of the antibody. 
 
2.4.1 Clonal Selection 
There are multiple laboratory technologies capable of high-throughput screening of 
populations of antibodies against a single antigen of interest, and most are based on assays 
that test the physical affinity between the two molecules. Phage display is an in vitro 
technology that involves the insertion of a protein-encoding gene into a bacteriophage, 
which then presents the protein on the surface of its coat, making it functionally similar to 
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MHC presenting an antigen [17]. These protein-presenting bacteriophages can then be 
screened against different proteins immobilized to a surface (such as a well plate). 
Spontaneous binding activity followed by subsequent washing allows for isolation of 
bound bacteriophages which can be sequenced to identify the gene that encodes for the 
high-affinity antibody, shown in Figure 2.7. This technique was pioneered by Sir Gregory 
Winter in the 1990’s and has enabled the development of multiple FDA-approved 
humanized antibodies since the early 2000’s; he ultimately received a Nobel Prize for this 
work in 2018 [18]. 
        Another method of identifying high affinity therapeutic mAbs is to screen for them in 
human primary cells. This technique allows for the identification of fully human mAbs 
against a specific disease antigen by collecting a blood sample from a patient that has 
exhibited a successful recovery, negating the need for humanization [11]. First, B-cells 
(which make up approximately 5-10% of a PBMC sample) must be isolated using 
automated sorting techniques, such as flow cytometry [19]. The obtained population of B-
cells is heterogeneous and therefore must be further sorted into single cells. The antibodies 
produced by these single cells can be screened for using techniques previously discussed. 
Fully human mAbs may also be screened for in transgenic mice hybridomas, which have 
been genetically modified to produce antibodies with the structural makeup and post-
translational modifications of mAbs produced by humans. These techniques are also shown 
in Figure 2.7. 
 
  15 
 
Figure 2.7: Human mAb Development Techniques (created using BioRender) [11], [20] 
 
2.4.2 Creating an Expression Plasmid 
After selecting the desirable mAb clone, the next step is to create robust mammalian cell 
factories that can produce large enough amounts to meet high industry demand. Immortal 
cell lines with well-characterized nutritional needs and metabolisms must be transfected 
with an expression plasmid for the mAb of interest. To achieve this, the gene that encodes 
for the variable regions of the light and heavy chains of the mAb must be amplified and 
sequenced; cDNA containing this sequence can be inserted into an expression plasmid 
alongside a promoter and a selection gene, which can be used to transfect robust 
mammalian cell lines for mAb production (Figure 2.8) [21]. 
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Figure 2.8: Creation of Human mAb Plasmid (created using BioRender.com)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 
2.4.3 CHO and NS0 Cells 
The production of full-length therapeutic mAbs is largely carried out using two cell types 
– Chinese hamster ovary (CHO) and non-secreting murine myeloma (NS0) cells. CHO 
cells account for over two-thirds of industrial mAb production alone, while NS0 cells 
account for most that remain [22]. While both cells can exhibit stable growth in serum-free 
suspension cultures, CHO cells are comparatively more robust and can express mAbs that 
possess human-like posttranslational modifications. One downfall of NS0 cells is that they 
incorporate certain molecules into their glycosylation patterns that are immunogenic in 
humans, limiting their efficacy [23]. In comparison, CHO cells have been shown to 
incorporate lower levels of immunogenic molecules, rendering them more practical for the 
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production of biologic therapeutics for humans. Additionally, CHO cells are bereft of viral 
entry genes that make NS0 and other mammalian cells susceptible to viral infection, 
enhancing their robustness by mitigating this risk in cultures [24].  These advantages have 
led to the rapid characterization of CHO cells, including genomic sequencing in 2011 and 
the publication of extensive omics analysis in the years immediately following [25]. These 
advancements have crafted a formidable argument for the selection of CHO cells (and to a 
lesser extent, NS0 cells) for the synthesis of mAbs using engineered expression plasmids 
for high-affinity clones. 
 
2.4.4 The Glutamine Synthetase (GS) Selection System 
CHO and NS0 cells lack the natural ability to perform the catalysis of glutamine from 
ammonia and glutamate, so their culture media must be supplemented with it in order for 
them to survive [26]. This characteristic has been exploited for the specific selection of 
cells that are capable of mAb production by coupling a gene for the glutamine synthetase 
enzyme with the mAb gene in the expression plasmid [27]. Therefore, when cultured in 
glutamine-free media, only cells that have been successfully transfected will continue to 
survive and proliferate. Cells that are particularly high-producing can be further selected 
for by the incorporation of L-methionine sulfoximine (MSX) in the culture media, which 
is known to inhibit the activity of glutamine synthetase. The DHFR selection system is also 
widely used in the biopharmaceutical industry, but it is not relevant to this thesis because 
only GS-CHO and GS-NS0 cell cultures were analyzed [28].  
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2.4.5 Scale Up of mAb-Producing Cell Cultures 
Mammalian cells that produce therapeutic mAbs are grown in suspension cultures and are 
capable of very high cell densities while maintaining above 90% viability. To accomplish 
this, a cell line that is capable of consistent, high production of a mAb of interest must be 
constructed. First, an industrial mammalian cell line with an existing selection system (ex: 
GS-CHO) is transfected with an expression plasmid designed for a specific mAb. The 
transfected cells are then cultured in selection media and expanded over the course of 
multiple weeks. The highest-producing clones are identified and selected for further 
expansion during this process [29]. Once the ideal clones have been iteratively selected for 
and expanded over weeks, small-volume aliquots are placed in cryopreservation tanks to 
create a master cell bank (Figure 28.3A). Individual vials are taken from this master cell 
bank for the creation of working cell banks. Cryopreserved cells are typically first 
inoculated in small-volume shake flasks in batch culture. Once a higher cell density in 
flasks has been achieved, the cells are passaged into a small seed bioreactor and cultured 
to high density once again. This process is iteratively repeated with larger and larger seed 
bioreactors until they are finally passaged into the final production bioreactor, which is 
typically hundreds or even thousands of liters in volume (Figure 28.3B) [30]. After the 
final culture falls below an undesirable viability threshold, cells and solid debris are 
removed via centrifugation and filtration, and the recovered spent media is preserved for 
downstream processing (namely mAb purification) [31]. 
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Figure 2.9: Clonal Selection and Scale-Up (created using Biorender.com) [30] 
 
2.5 Current Manufacturing Practices and Future Optimization Strategies 
Many improvements have already been implemented to enhance cell density and viability, 
as well as mAb titer and quality. For example, transitioning to serum-free media greatly 
improved the reproducibility of cultures by eliminating a large source of variability in 
media composition [32], and predictive mathematical modeling of cellular processes has 
been shown to save significant time and resources in the optimization of culture conditions 
[33], [34]. This section briefly summarizes broadly important advances that have been 
made and are continually being developed for industrial mAb production. 
 
2.5.1 Single-Use Bioreactors and Improving Process Monitoring and Control 
The implementation of bioreactors in place of shake flasks alone introduces significant 
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advantages in mAb-producing mammalian cell culture, but the size, build and functionality 
of bioreactors is very diverse. In a more recent development, many bioreactor 
manufacturing companies are transitioning their focus towards single-use bioreactors 
instead of reusable stainless steel. In a large-scale industrial setting, single-use bioreactors 
are attractive because they greatly reduce the risk of contamination [35]. With stainless 
steel bioreactors, the vessels must be extensively cleaned and sanitized between cultures to 
avoid contamination, and there remains risk. Single-use plastic bioreactors are sterilized 
before or on arrival and are disposed of after a single use, reducing the time and resources 
required for cleansing and sanitation as well as eliminating risk of contamination in the 
next culture. The employment of single-use sterile connectors for tubing and ports in 
bioreactors are also a necessary inclusion for the maintenance of sterility during 
inoculation, sampling and feeding of a culture.  
        Peripheral technologies for the real-time online monitoring and control of important 
process parameters such as pH, gas cascade intensity, dissolved O2, temperature and 
agitation speed (for suspension cultures) make it increasingly easier to maintain robust and 
automated process control with the development of user-friendly and industry-standard 
software. The continuous improvement of bioreactor design and process control and 
monitoring technologies will allow for enhanced and reproducible production of mAb 
products. 
 
2.5.2 Fed-Batch, Continuous and Perfusion vs. Batch Cultures 
In an industrial setting, batch cultures are far and away the most widely employed for mAb 
production due to their simplicity and long history of success. However, fed-batch cultures 
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improve on them in principle by supplying key nutrients to prevent depletion, but this 
increases the culture volume. Continuous cultures employ a similar strategy, but an equal 
volume being added is removed beforehand to avoid increasing the working volume and 
diluting the culture; however, this results in a decrease in total viable cell number at the 
time of feeding. Perfusion culture techniques improve upon this by filtering out spent 
media and cell debris while retaining whole cells. A visual comparison of these culturing 
methodologies is shown in Figure 28.3C. 
 
 
Figure 2.10: Modes of Culturing (created using BioRender.com) [36] 
 
Implementation of these techniques is very sensible on paper, but actual incorporation into 
industrial production processes requires extensive development time and costs, as well as 
optimization – which is why batch cultures are still preferred by many businesses [1]. 
However, the long-term sustainability and prospects of fed-batch and continuous 
technologies have pushed some large biotechnology companies who are able to absorb the 
high upfront costs and technology transfer to transition more of their processes away from 
batch methodologies [1]. 
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2.5.3 Omics Characterization 
Comprehensive characterization of cell lines is a critical factor in the optimization of their 
culturing. Developing a greater understanding of the compositional and behavioral 
characteristics is a necessary first step in better accommodating their growth and 
productivity needs by means of optimized process parameters. Metabolomics broadly 
describes the large-scale quantification of small molecules that serve as substrates, 
intermediates, or products of metabolic processes in the cell – together, these make up the 
metabolome. Liquid chromatography-mass spectrometry (LC-MS) is the most widely 
applied method for metabolomics, but other technologies such as nuclear magnetic 




Figure 2.11: Omics Characterization of Cell Lines (created using BioRender.com) [38] 
 
Proteomics similarly describes the large-scale identification and quantification of proteins 
that are produced by a culture of cells. Since proteins are expressed for a variety of 
purposes, proteomics can be used to characterize both the functional and structural 
proteomes. Gel electrophoresis and SDS-PAGE are commonly used for protein expression 
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profiling, and mass spectrometry used in tandem with chromatographic methods (such as 
liquid chromatography) is used for the isolation and structural characterization of proteins 
[39].  
        Genomics and transcriptomics, which entail the mapping and characterization of a 
cell’s DNA and transcribed RNA through means of PCR, DNA microarrays, next-
generation sequencing and RNA-sequencing can help further develop the understanding of 
a specific cell line’s genome and functional transcriptome at key developmental and 
metabolic stages.  
        Lipidomics describes the chromatographic separation and subsequent identification 
and quantification of specific lipids by means of mass spectrometry or NMR. This study is 
important because, like proteins, lipids contribute significantly to not only structural 
composition (namely phospholipid membranes) but also cellular metabolism. All of these 
“omics” techniques, visualized in Figure 2.11, can be employed to develop comprehensive 
maps of cellular characteristics during different stages of both successful and failed 
cultures. Characterization on such a large scale requires collaborative effort between 
international research communities, of which projects like the regularly updated 
CHOgenome.org for the conglomeration of CHO genomic data are a prime example [40].   
 
2.5.4 Media Design and Feeding Strategy Optimization 
Culture media serves the purpose of providing sole exogenous support of key nutrients and 
macromolecules to cultured cells, and therefore its composition is extremely important to 
the optimization and success of mAb manufacturing. The relative concentrations of 
vitamins, amino acids, buffer salts, lipids and trace metals can yield significant impact on 
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the productivity and viability of cultured cells, and many cell lines are very sensitive to any 
compositional deviations. It has been found that the substitution of serum-supplemented 
media in favor of serum-free chemically defined media greatly enhanced the 
reproducibility of cultures by eliminating a significant source of compositional variation 
between bottles of the same culture media, which is especially critical for the maintenance 
of robust bioprocessing [32]. However, given that no two cell lines have identical 
nutritional needs, an important step in the optimization of mAb production is the 
determination of media composition that is tailored to meet the specific growth and 
productivity requirements of any given industrially relevant cell line.  
        This optimization can be informed by experimental observation of the dynamic 
consumption and production of media components and cellular metabolites in tandem with 
“omics” data described previously. The identification of significant shifts in a culture’s 
metabolic behavior under different conditions elucidates either the excess or deficiency of 
key nutrients - both of which can result in growth inhibition, poor productivity, and the 
accumulation of toxic metabolites such as lactate and ammonia. It has been shown that 
media optimization alone can result in significantly enhanced volumetric productivity of 
mAb-producing cell lines by precisely meeting the nutrient requirements for cellular 
maintenance and proliferation, mAb production and energy metabolism [34].  
 
2.5.5 Design of Experiments Methodology  
Intracellular biochemical processes have been extensively mapped to better understand 
their needs and behavior, and researchers have also been able to apply mathematical 
equations to describe their dynamic relationships. This is one of the most important and 
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fastest-growing areas of bioprocess development and optimization because it enables in 
silico optimization through predictive modeling as opposed to empirical approaches like 
design of experiments (DOE) methodology. In short, DOE is an optimization strategy that 
uses applied statistics to generate an array of different experimental conditions that result 
in the comprehensive testing of multiple process parameters in a highly controlled manner. 
This systematically evaluates each parameter and its impact on the process responses (such 
as mAb yield or cell density) to maximize productivity and minimize variability. A 
technique known as factorial design is used to determine which factors (synonymous to 
independent variables) are to be varied during experimental runs and how many levels will 
be tested (ex: low, medium, high). Each experiment, or run, involves the application of a 
unique combination of factor levels, referred to as a treatment. Below is an example of a 
design matrix, which serves to visually depict the treatments to be applied for each run in 
an experiment.  In this case, the authors employed 33 factorial design because three factors 
were tested (cell concentration at induction, CuSO4 concentration at induction, and harvest 
time) each at three different levels, in an attempt to maximize percent menin expression in 
Drosophila melanogaster S2 cells [41]. It is important to note that while there are 27 
possible treatments for this design, only 10 runs were carried out by the authors; this is an 
example of fractional factorial design, in which a subset of treatments from the full factorial 
design are chosen to emphasize importance on the variables most likely to have the greatest 
impact while minimizing time and costs. Screening experiments can be employed to 
identify significant factors to focus on for fractional factorial design, as is very commonly 
observed in clinical research [42]. 
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Table 2.1: Example of Factorial Design  
 
 
2.5.6 Model-Based Optimization 
While DOE-based optimization is ultimately successful, it often requires that hundreds of 
potentially unsuccessful runs are conducted for comprehensive testing, which is costly in 
terms of both time and resources. Conversely, model-based optimization saves time and 
resources by mathematically simulating experimental results and outcomes based on 
known and derived equations that describe cellular behavior. These equations can reflect 
known mass balance principles for various biomolecules and their required proportional 
uptake for key cellular functions such as structural maintenance, mAb production and 
energy metabolism [34]. For example, the biomass composition of a specific cell line can 
be experimentally determined by the isolation and digestion of dry cell mass and sequential 
processing for quantification of amino acids, proteins, lipids, and carbohydrates content 
per cell. Similarly, the molecular composition of monoclonal IgG antibodies can be 
determined, and published information is already available. Applying these biomolecular 
Culture Cell concentration at 
induction (107 mL-1) 
CuSO4 concentration 






1 0.5 0.2 1 3.93 
2 0.5 0.7 1 2.35 
3 0.5 0.2 6 1.29 
4 0.5 0.7 6 52.08 
5 1.5 0.45 3.5 69.52 
6 1.5 0.45 3.5 18.35 
7 2.5 0.2 1 100 
8 2.5 0.7 6 3.56 
9 2.5 0.2 6 1.73 
10 2.5 0.7 1 84.80 
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mass requirements in combination with known metabolic reactions allows for the dynamic 
predictive modeling of cellular allocation of nutrients, mAb productivity, proliferation, and 
toxic metabolite accumulation. Many different research groups and companies have 
recently made large strides within this area, and further experimental validation and 
evolution of computing capabilities will enable even greater potential for in silico 
bioprocess optimization. This will be critical in meeting the increasing demands of the 
expansive mAb market. 
 
2.6 Multivariate Analysis Techniques 
Since bioprocess optimization requires the consideration of many variables, multivariate 
analytical techniques are helpful in elucidating clusters of similarity between variables and 
between samples in a large dataset. Multivariate analysis is an umbrella term used to 
describe many statistical analysis methods for multivariate data, but the work in this thesis 
applies only two specific methods: principal component analysis (PCA) and hierarchical 
clustering analysis (HCA). 
 
2.6.1 Principal Component Analysis 
This analysis is a method for dimensionality reduction, meaning that is transforms a large 
dataset into a much smaller dataset of new variables that are orthogonally related and still 
capture a significant fraction of the variation in the original variables – these new variables 
are called principal components [43]. For this to be possible, the original variables must be 
standardized to be comparable, and this is performed by first calculating the z-score for 
each entry of data [44]. The equation for calculating the z-score is shown below: 






The z-score standardizes each variable by scaling them down to be comparable, giving 
each column of data a mean of zero and a standard deviation of 1. Due to the sensitivity of 
PCA, variables with much higher magnitudes would eclipse variables of smaller magni-
tude, making them appear much more significant than they likely are, so standardization is 
important in most cases to ensure the accuracy of PCA. Next, the covariance matrix S for 
the standardized variables must be computed using the following equation, where n denotes 







 The eigendecomposition (extraction of eigenvalues and eigenvectors) of the covariance 
matrix S are then used to determine the principal components of the data. The eigenvalues 
are stored in matrix D and eigenvectors in diagonal matrix P, for the purpose of discussion. 
The values in matrix P are then sorted based on the magnitude of the corresponding eigen-
vector in matrix D, with the largest eigenvalue dictating the placement of its corresponding 
eigenvector in the first column of diagonal matrix P and iteratively repeating with the next 
largest eigenvalue until the matrix of eigenvectors is sorted in descending order [45]. Ma-
trix U (which stores the original standardized variables) is then multiplied by re-ordered 
matrix P to produce the one-dimensional matrix of principal components, or PC scores; the 
values of the eigenvectors denote the PC loadings [45]. Geometrically, these principal 
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components are linear combinations of all of the original variables and are orthogonal from 
one another, meaning that each one is entirely independent. The first principal component 
is the one that is able to capture the most variation in the original data, with each following 
principal component capturing a diminishing amount.   
        An easy way to conceptualize PCA is to imagine that each variable is plotted on its 
own axis in space (such that ten variables would translate to ten theoretical dimensions). 
The first principal component is created by drawing a line through this ten-dimensional 
space that is as close to as many of the data points as possible, and the projections of the 
original data points onto this line represent their new values for this principal component. 
A new line is then drawn in an orthogonal direction from the first line that is, once again, 
as close to as many of the original data points as possible. This process is repeated as many 
times as desired. Each principal component captures a percentage of the total variance 
within the original data, and this percentage is very important when determining their sig-
nificance. The power of PCA becomes clear when PCs are visualized together, and for the 
work in this project I opted to include only the first two, since these alone were able to 
capture a majority (>50%) of the variation in all cases. This visualization can elucidate 
clusters of similarity in the data, highlighting which cell culture samples are similar and 
different from one another when accounting for all variables, at the cost of explicit clarity 
regarding which original variables are the significant contributors. In this thesis, existing 
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2.6.2 Hierarchical Clustering 
Hierarchical clustering is an analysis that, similar to PCA, is used primarily to identify 
clusters of similarity in a standardized dataset. It can be performed using numerous meth-
ods which are broadly categorized into two groups: agglomerative (bottom-up) or divisive 
(top-down) [46]. Agglomerative algorithms initially consider every row or column of data 
points as an individual cluster, and iteratively form additional clusters based on a similarity 
metric. Euclidean distance was the selected metric for this work, and it describes the dis-
tance between two points in n-dimensional Euclidean space which can be calculated using 
the following equation, where p and q represent a row or column and i represents a single 
entry within each [47]: 
 
𝑑(𝑝, 𝑞) = 	<(𝑝" −	𝑞")# +⋯+	(𝑝$ −	𝑞$)#	 (2.3) 
 
The Euclidean distance between two rows or columns describes their similarity and is uti-
lized to ultimately determine the linkage between clusters. Complete linkage criteria, se-
lected for this work, requires that the distance between two clusters be defined by the max-
imum Euclidean distance that every pairwise combination of cluster elements can achieve. 
This means that the distance between clusters is determined not by their two closest ele-
ments (single-linkage) or the average of all elements (average-linkage), but rather their two 
farthest elements [48]. Combining the two most similar clusters is performed in a stepwise 
manner until all the data is merged into a single cluster that branches off into progressively 
smaller clusters, visually represented by a tree-like dendrogram. Complete linkage is one 
of the most commonly employed methods in hierarchical clustering algorithms and is 
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known to produce more compact clusters, which is helpful for this project in the endeavor 
to identify specific patterns and linkages in metabolic behavior [46]. Hierarchical cluster-
ing can be conducted horizontally or vertically across a data frame, which will be shown 
in the upcoming chapter. Dendrograms generated from the HCA are depicted along their 
respective axis against a heatmap of the standardized data matrix, which visualizes the time 
horizons of each variable using a color spectrum for easier pattern identification. All data 
must be standardized such that magnitudes do not impact the Euclidean distances. 
 
2.7 Applications of Monoclonal Antibodies 
Their high affinity and specificity yield great potential for many diverse applications of 
mAbs as a clinical tool. They have been shown to be capable of neutralizing a wide variety 
of diseases, but their usefulness extends beyond purely therapeutic applications. 
Monoclonal antibodies are also a powerful diagnostic tool and can even be used to augment 
existing medicines to enhance their efficacy by enabling specific targeting. A brief 
overview of the different application areas of mAbs will be discussed in this section, and a 
table of the most profitable mAb therapies is also provided. 
 
2.7.1 Treatment and Diagnosis of Cancers 
Oncology remains the most relevant and profitable sector of mAb applications with the 
highest recorded and projected sales of all other mAb application areas by far [49]. One 
proven mechanism is the targeting of human epidermal growth factor receptor 2 (HER2), 
an important component in breast cancer cell signaling, as shown by the commercially 
successful trastuzumab (developed and marketed as Herceptin by Genentech). Another 
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blockbuster Genentech therapeutic, Avastin (generically known as bevacizumab), targets 
vascular endothelial growth factor to similarly inhibit the cellular signaling of multiple 
cancers. Both drug products were within the top five grossing mAb biologics in 2018 [49].  
        Recent breakthroughs in mAb treatments for cancer immunotherapy by Merck and 
Co. and Bristol-Meyers Squibb selectively inhibit the programmed death 1 (PD-1) immune 
checkpoint, a surface protein on T and B cells which downregulates T cell inflammatory 
activity upon activation of the T cell receptor [50]. While PD-1 is important for homeostatic 
control of adaptive immunity, it is exploited by cancer cells to limit the immune response 
against them; thus, anti-PD-1 mAbs such as pembrolizumab and nivolumab are promising 
solutions [49]. Systemic administration of anticancer mAb therapeutics can be achieved by 
the exploitation of the enhanced permeability and retention (EPR) effect of tumors on their 
surrounding blood vessels, which essentially describes a leakiness which results from 
upregulated VEGF expression and weak structural integrity as a product of uncontrolled 
growth [51]. IgG antibodies are small enough to fit through the vessel gaps created by this 
phenomena, allowing for passive delivery of mAbs to the tumor microenvironment through 
systemic injection. 
 
2.7.2 Monoclonal Antibodies as Immunomodulators 
Immunomodulating monoclonal antibodies can be administered to treat other immune 
disorders outside of cancer. Drugs that selectively inhibit inflammatory cytokines such as 
tumor necrosis factor (TNF) have exhibited success in medicating against multiple 
autoimmune disorders, such as Humira (adalimumab) for the treatment of rheumatoid 
arthritis [52]. While Humira is by far the most commercially successful, there exist several 
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other TNF-blocking mAb drug products for the treatment of other autoimmune diseases 
such as ankylosing spondylitis, psoriasis and Crohn’s disease [49]. The significance and 
prevalence of various interleukins, which are immunomodulating cytokines, have also 
made them an attractive target for autoimmune mAb therapies. Successful mAbs on the 
market which selectively target IL-12/IL-23, IL-17, IL-5 and IL-4a (to name a few) are 
used for the treatment of autoimmune diseases previously described in addition to others 
such as asthma and dermatitis [51]. 
 
Table 2.2: Top 10 Selling mAb Therapeutics 





Rheumatoid arthritis (2002)  
Psoriatic arthritis (2005)  
Ankylosing spondylitis (2006)  
Juvenile Idiopathic Arthritis (2008)  
Psoriasis (2008) 
Crohn’s disease (2010)  
Ulcerative colitis (2012) 






Non-small cell lung cancer (2015)  
Renal cell carcinoma (2015) 







Head and neck cancer (2016) 
Non-small cell lung cancer (2015) 
Lymphoma (2018) 
Cervical cancer (2018) 






Breast cancer (1998) 




Colorectal cancer (2004) 
Non-small cell lung cancer (2006)  
Breast ERB2 negative cancer (2008)  
Renal cell carcinoma (2009)  
Glioblastoma (2011) 
Roche 
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Table 2.2: Top 10 Selling mAb Therapeutics (Continued) 
6 Rituximab 
(Rituxan) 
Non-Hodgkin’s lymphoma (1997) 
Chronic lymphocytic leukemia (2010) 
Rheumatoid arthritis (2006)  




Crohn’s Disease (1998)  
Rheumatoid arthritis (1999)  
Ankylosing spondylitis (2004)  
Ulcerative colitis (2005) 








Psoriatic arthritis (2013) 






Paroxysmal nocturnal hemoglobinuria 
(2007) 
Atypical hemolytic uremic syndrome 
(2011)  
Generalized myasthenia gravis (2017) 










2.7.3 Other Clinical Applications 
While inhibitory monoclonal antibodies can exhibit therapeutic effects on their own, not 
all are neutralizing agents. Instead, they can be incorporated into drug product formulations 
to provide selective delivery for active pharmaceutical ingredients which are cytotoxic, 
which enhances efficacy and mitigates unwanted side effects. They are becoming 
increasingly relevant in nanoparticle-based delivery systems, because the encasing of the 
drug within the nanoparticle (which are often synthesized from organic polymers, lipids, 
or gold) offers enhanced stability during systemic circulation while the surface mAbs 
selectively bind to the disease antigen, offering and maintaining close proximity of the 
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cytotoxic drug to its target [53]. There is much work still to be done within this research 
area, but there are multiple nanoparticle-based drug-antibody conjugates in development 
that have shown promise in the treatment of breast and ovarian cancers [54] [55]. 
 
2.7.4 Diagnostic and Non-Clinical Applications 
Monoclonal antibodies are an exciting addition to the pharmaceutical world, but they are 
also present in many diagnostic applications and common lab technologies. They serve as 
the backbone for enzyme-linked immunosorbent assays (ELISAs), which utilize mAbs that 
are conjugated to an immobilized antigen and coupled with a reporter enzyme that can 
detect the presence of a specific substrate, such as a hormone or antibody, when incubated 
with a biological sample [56]. ELISA is the technology most commonly incorporated in 
pregnancy tests but can also be used in a wide variety of other diagnoses. Monoclonal 
antibodies can also be found in Western blots, flow cytometry, fluorescent microscopy, 
and affinity chromatography columns [57]. 
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CHAPTER 3 
 





Before experimental work for this thesis began, the multivariate analysis techniques were 
developed by practicing with existing data collected by a postdoctoral researcher in our 
lab. Quiroga et al. cultured GS-NS0 cells for the development and validation of a predictive 
mathematical model to optimize culture media and feeding strategies for fed-batch cultures 
of mammalian cells, based on over one hundred metabolic, ATP and mass balance equa-
tions [34]. The model is reliant on data collected from an initial batch culture, after which 
it performs parameter estimation to output a recommendation for basal media supplemen-
tation and a feeding strategy for a fed-batch culture of the same cell clone. These conditions 
were then experimentally applied in an “unoptimized” fed-batch culture, during which 
more data is collected for the model. A new media supplementation and feeding strategy 
was output, which were applied in an “optimized” fed-batch culture to enhance its longev-
ity and, ultimately, mAb titer. Quiroga et al. reported in their 2018 paper that model-based 
optimization successfully increased the mAb titer in a fed-batch culture of GS-NS0 cells 
by as much as 167% and extended the culture longevity by two days [58]. The data from 
the unoptimized and optimized cultures will be compared using unsupervised multivariate 
analysis techniques. 
 
3.2 Aim and Objectives 
The aim of this chapter is to successfully program a multivariate analysis platform which 
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is capable of receiving experimental data and automatically computing and visualizing re-
sults from HCA and PCA. To achieve this, a software tool must first be selected that is 
capable of preparing the data and performing the required analysis. Specifically, a method 
for data standardization by calculating z-scores from raw data will need to be programmed, 
and data split across multiple files (as was the case for the unoptimized and optimized 
cultures) must be joined. Then, an algorithm for calculating the principal components ma-
trix will be programmed and the percent of variance captured by each will be subsequently 
calculated. An agglomerative hierarchical clustering method using a Euclidean distance 
similarity metric and complete-linkage criteria must also be programmed to generate both 
horizontal and vertical dendrograms for the standardized data matrix. Lastly, a method or 
package will need to be developed or selected to clearly visualize the results from the PCA 
and HCA. The data collected by Quiroga et al. will be analyzed using this developed plat-
form, which will hopefully validate the findings reported in their publication as well as 
potentially extract new findings. 
 
3.3 Materials and Methods 
3.3.1 Programming in RStudio 
RStudio software was chosen due to the lack of a paywall and extensive availability of 
existing resources for learning and programming. RStudio is the most widely used software 
for writing and running code using the R programming language, which was designed for 
statistical analysis and data visualization.  
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3.3.2 Data Input and Processing 
The data was exported from Excel into .CSV format in order to be input and processed in 
RStudio using the read.csv() function, which places the rows and columns into a dataframe 
as they were arranged in the Excel file. Two separate data frames were created - one each 
for the unoptimized and optimized culture data. Each set of data represents the mean values 
calculated from three replicate cultures and measured 26 independent variables: all 20 
amino acids sans glutamine (mM), ATP (mM), viable/apoptotic/dead cell densities 
(cells/mL), glucose (mM), lactate (mM) and mAb titer (mg/L). All values that were zero 
were replaced by 1x10-20, being on average 17-20 orders of magnitude smaller than the 
smallest nonzero value in the column to avoid problems with dividing by zero during stand-
ardization. Then, datasets were merged and standardized using the unite() and scale() func-
tions respectively. The scale() function standardizes the data using the z-scoring method-
ology previously described in section 2.6.1, and unite() appends one dataframe to the other. 
There were 28 observations of each independent variable per unoptimized culture and 24 
observations recorded for each optimized culture – therefore, in the final averaged and 
merged dataset analyzed in this chapter, there were a total of 52 observations for each of 
the 26 independent variables. 
 
3.3.3 Hierarchical Clustering Analysis 
Hierarchical clustering of the data was performed by nesting the dist() function, which 
calculates the distances between each row of data, inside the hclust() function to generate 
a dendrogram that sorts the samples based on their similarity across all variables. A condi-
tion was provided inside the dist() function to specify Euclidean distance as the desired 
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metric.  The generated dendrogram was then displayed alongside a heatmap that was cre-
ated using the heatmap.2() function in the “ggplots” package. A function argument speci-
fying the inclusion of a dendrogram along the vertical axis, which sorts variables based on 
the similarity of their z-score profiles to one another, was also added. The z-score for each 
data point is visualized with a red/blue gradient in the heatmap such that dark blue repre-
sents a z-score that is significantly less than the column’s mean and dark red represents a 
z-score significantly greater than the column’s mean. The largest and most significantly 
different clusters have been boxed and color-coded for ease of visualization.  
 
3.3.4 Principal Component Analysis
The principal components matrix was generated using prcomp() from the “stats” package. 
The percentage for each principal component was calculated using equation 3.1, where i 
denotes either the first or second PC: 
 
𝑃𝐶" 	% = 	
(𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑃𝐶")#
∑ 𝑃𝐶"#"%#"%&
	× 	100	 (3.1) 
 
PCA visualization was performed using a scatterplot, with PC1 on the x-axis and PC2 on 
the y-axis. To generate the graphs, the geom_point() function in the “ggplot” package was 
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3.4 Results 
3.4.1 Hierarchical Clustering Analysis 
Figure 3.1 visualizes the results of the hierarchical clustering. The color-coded boxes cor-
respond with the boxes in the plots for viable cell density in Figure 3.2. The horizontal 
labels are sample IDs which denote whether the sample was taken from the unoptimized 
or optimized culture, followed by the number of hours after the start of the culture that the 
sample was taken. The vertical labels indicate the measured variables that correspond with 
each column.  
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Figure 3.1: HCA of Unoptimized vs. Optimized NS0 Fed-Batch Cultures 
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Figure 3.2: Viable Cells for Unoptimized vs. Optimized NS0 Fed-Batch Cultures 
 
Initially, it must be noted that the major clusters of samples identified by the HCA corre-
spond very closely with the four stages of growth commonly observed for cultured cells: 
lag, exponential growth, stationary, and decline/death. It can be seen that the lag phases of 
both cultures (first 24 hours) cluster together, but after 48 hours the concentration profiles 
of the two cultures diverged and were no longer statistically similar. Another notable ob-
servation is that the clusters for the unoptimized culture were exclusively sequential, mean-
ing that there was no overlapping of clustered data points over time. This contrasts with 
the optimized culture, which as can be seen in Figure 3.2, possesses overlapping early and 
late exponential phases. Specifically, the feedings at 96 and 108 hours caused the next 
days’ samples to cluster broadly with the samples collected during the early exponential 
phase (in pink) instead of the late exponential phase (in red), signifying that the optimized 
supplementation in these feedings reverted the cultural conditions to be more similar to 
what is observed during earlier stages of exponential growth. However, it is important to 
note that the early exponential phase for the optimized culture is metabolically distinct 
from that of the unoptimized culture and instead clusters with the late-stage exponential 
growth of the unoptimized culture, rather than its early-stage growth. Overall, the heatmap 
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displays relatively lower concentrations of many amino acids in the optimized media com-
pared to their respective time points in the unoptimized culture. 
 
3.4.2: Principal Component Analysis 
The PCA results are visualized in Figure 3.3 on the following page. The clusters of data 
points have been manually color-coded and circled to correspond with the same clusters 
identified in the HCA. These results clearly show that there is a significant difference be-
tween the unoptimized and optimized fed-batch cultures across all of the collected data. 
First, it is notable that PC1 and PC2 collectively account for approximately 68% of the 
variation within the original dataset of 24 variables, bolstering the significance of the clus-
ters in the graph. The key for the data points shown below the graph is ordered by culture, 
and each point is color-coded to correspond with the significant clusters identified in the 
HCA. This allows for clear visualization of the transition into the different growth phases 
within each culture and successfully showcases the shifting metabolic profiles between 96 
and 127 hours in the optimized culture. It can be seen that after 48 hours, all of the data 
points for the optimized culture are significantly segregated from the unoptimized culture 
clusters. Interestingly, the most divergent clusters between the cultures are those represent-
ing the early exponential growth (denoted by the pink and green data points), highlighting 
the immediate difference between feeding strategies.  
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3.4.3 Effect of Optimization on Culture Longevity, Density, and Productivity 
The resulting viable cell densities and mAb titer for each culture are visualized in Figure 
3.4. The optimized fed-batch culture exhibited increased longevity and maximum viable 
cell density, both clear benefits of the model-based media design and optimized feeding 
strategy. Enhanced benefits are also reflected in the mAb titer as well, as the optimized 
fed-batch culture achieved a maximum mAb concentration of over 300 mg/L while the 
unoptimized fed-batch culture achieved approximately 225 mg/L.  
 
 
Figure 3.4: Enhanced Longevity and Productivity in Optimized NS0 Culture [34] 
 
3.5 Discussion 
The clustering of the lag phases in both the HCA and PCA is not surprising, given that 
neither culture has been supplemented with feedings yet and both cultures would need to 
similarly adjust to inoculation in the bioreactor under the same experimental conditions 
(sans basal media supplementation). Likewise, the divergence of the cultures not long after 
this point is also sensible given the timing that the feeding strategies were implemented. 
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optimized culture is significant because it shows that the optimized feeding strategy more 
significantly affected the metabolic behavior of the cells compared to the unoptimized 
strategy. This period of shifting between early and late exponential growth metabolic be-
havior is ideal because it shows that the culture is resistant to a permanent shift towards 
stationary growth, and earlier stages of growth are often when cells are the most productive 
because there are adequate exogenous nutrients to support rapid division and mAb produc-
tion. The optimized feeding strategy was designed to limit the excess of nutrients in culture 
media, forcing the cells to sustain a more controlled metabolic state in moderate concen-
trations of nutrients. The advantageous results of the optimized media composition and 
feeding strategy compared to those that were unoptimized verifies existing observations 
that an excess of nutrients may initially promote rapid growth that is unsustainable and will 
ultimately induce a state of metabolic stress, negatively impacting culture longevity and 
volumetric productivity.  
        The ability to elucidate clusters of metabolic similarity within and between cultures 
from unsupervised analysis, which happen to broadly correspond to the phases of cell 
growth, is very interesting. This unbiased approach to the critical analysis of cell culture 
for the production of a specific mAb will be explored in greater depth in the coming chap-
ters. GS-CHO cells will be cultured for the purposes of characterizing their metabolic be-
havior in chemically defined media. The identification of metabolic shifts will allow for 
the determination of key nutrients which could be supplemented into the basal media to 
extend culture longevity by optimizing cell viability and volumetric productivity.  
        By limiting the excess of nutrients during exponential growth, the optimized feeding 
strategy promoted differential metabolic behavior that reduced cellular stresses and 
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enhanced culture longevity by two days. This ultimately resulted in approximately a 40% 
increase in volumetric productivity, as shown in Figure 3.4. These benefits are a testament 
to the success of the model-based optimization developed and performed by Quiroga et al., 
and the multivariate analytical platform applied to the data discussed in this chapter will 
be applied to new GS-CHO cultures moving forward to ultimately inform model-based 
parameter estimation to increase culture longevity, maximum viable cell density and mAb 
productivity. 
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CHAPTER 4 
 





After programming PCA and HCA methods for cell culture analysis based on existing data, 
the next step was to apply these analytical methods for the optimization of new cultures. 
GS-CHO cells were selected for the following experiments because there was an available 
allotment in cryopreservation from a previous lab member’s research. Additionally, GS-
CHO cells have significant industrial relevance for the production of mAbs and other re-
combinant proteins. The specific GS-CHO clone utilized in this experiment produces a 
rituximab biosimilar which, as discussed in section 2.6.2, was the sixth highest grossing 
mAb therapeutic in 2018 [49]. The cultures were maintained for a total of 10 days because 
it was at this point that the viability for all flasks fell below 50%. 
 
4.2 Aims and Objectives 
The aim of this chapter is to present the methods for the GS-CHO batch cultures and dis-
cuss the specific analytical techniques utilized for the collection of multivariate data. Start-
ing at the time of culture inoculation, spent media samples were collected, processed, and 
stored every 24 hours. The spent media samples collected and stored in the freezer daily 
were analyzed after termination of the culture flasks on day 10. The analytical methods 
described in the following pages serve the purpose of profiling the dynamic metabolic con-
sumption and production patterns of the GS-CHO cells. Specifically, the quantification of 
amino acids, glucose, toxic metabolites (lactate and ammonia), vitamins, ATP and mAb 
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concentrations in spent media were conducted in tandem with daily collection of growth 
and viability data. The results for viable cell density, ATP availability per viable cell, mAb 
productivity, and lactate, glucose and ammonia concentrations will be shown and discussed 
in this chapter while the specific results for amino acids and vitamins concentration will be 
woven into the discussion in Chapter 5. 
 
4.3 Materials and Methods 
4.3.1 Creation of a Cell Bank 
Multiple vials from the existing GS-CHO bank created by a previous student were thawed 
and cultured in small volumes, and unfortunately exhibited very low initial viability. Try-
pan Blue assays performed immediately after multiple inoculations confirmed that initial 
viability was, on average, well below 50%. However, viability over 50% was eventually 
achieved after multiple media exchanges (performed every other day), and once a viability 
over 90% was achieved, the cells were expanded from a working volume of 20 mL to 200 
mL. These cells were then transferred to cryopreservation media and banked at a concen-
tration of 1.5 x 107 cells/mL in 1 mL vials for usage in experiments. 
 
4.3.2 Inoculation and Culture Conditions 
Culture media was prepared beforehand by supplementing 980 mL of CD-CHO media with 
10 mL aliquots each of MSX and penicillin/streptomycin. For all experiments, two vials 
were briefly thawed at 37°C and inoculated in 20 mL of media in 125 mL Erlenmeyer 
flasks, resulting in a seeding concentration of 7.5 x 105 cells per mL. The cells were then 
passaged every two days into progressively larger volumes, first 60 mL and lastly in 200 
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mL with a seeding density of 4 x 105 cells/mL for every volume. Two days after passaging 
into 200 mL, each flask was split into two new 200 mL flasks to result in four total 1 L 
Erlenmeyer flasks containing 200 mL cultures at an initial density of 4 x 105 cells/mL. This 
seeding density was chosen because it was shown by a previous student in our research 
group to result in the highest maximum cell density during a 10-day culture when compared 
to lesser seeding densities [23]. These four flasks were kept in an incubator at 37°C, 5% 
CO2 and horizontal orbital shaking at 120 RPM.  
 
4.3.4 Daily Sample Collection 
The cultures were maintained for ten days each, and a strict daily sampling routine was 
maintained. First, 500 μL were collected from each flask for the purposes of immediately 
assessing cell density, viability, and ATP concentration. Then, 2 mL was collected from 
each flask and centrifuged at 200g for 5 minutes. 500 μL was collected from the supernatant 
and transferred into a microcentrifuge tube with 10 kDa filter insert and centrifuged for 
one hour at 1000 g and 4°C. This filtration step is critical to remove any cells or larger 
molecules because the samples will be analyzed using high-performance liquid chroma-
tography (HPLC) for the quantification of amino acids and vitamins. Another 500 μL sam-
ple was collected from the supernatant and filtered through a 45 μm filter attached to a 
syringe to remove any cells or cell debris for the purposes of HPLC quantification of mAb 
titer. Lastly, an unfiltered 700 μL sample of the supernatant was collected for the purpose 
of profiling metabolites using a benchtop BioProfile Flex 2 from Nova Biomedical. The 
flasks were then returned to the incubator and samples for HPLC and BioProfile analysis 
were stored in a -20°C freezer.  
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4.3.5 Determination of Cell Density, Viability and ATP Concentration 
The fresh, unfiltered 500 μL samples not stored in the freezer were used for immediate 
assay of viable cell number and ATP concentration. Cell viability was measured using a 
benchtop Guava EasyCyte Flow Cytometer with Guava Viacount reagent from Luminex. 
The Viacount reagent employs one “nuclear dye”, which stains nucleated cells (to distin-
guish cell debris from whole cells) and one “viability dye” (which distinguishes living and 
apoptotic cells from dead cells due to their differences in permeability). Samples were as-
sayed in duplicates in a 96 well plate. Viability and apoptosis gates were consistent for all 
samples, and were manually adjusted at ten days, after the final culture samples were run, 
to ensure accuracy in capturing the apoptotic and dead populations of cells. In parallel, 
ATP quantification was conducted using benchtop Glomax Luminometer and a CellTiter-
Glo Assay kit from Promega. The sample was mixed and incubated with CellTiter-Glo 
reagent and buffer in a 96 well plate and luminescence was subsequently measured. ATP 
concentration was determined from the luminescence readings using ATP standards to gen-
erate a calibration curve. 
 
4.3.6 HPLC Quantification of mAb Production 
The mAb concentration in supernatant samples was determined using HPLC. The machine 
used was an Ultimate 3000 system from Thermo Fisher Scientific, with the diode array 
detector (DAD) attachment for detection of amino acids using UV-Vis spectrophotometry. 
Machine programming and operation were conducted using Chromeleon 7 software. The 
MAbPac Protein A column from Thermo Fisher was used for the isolation of mAb product, 
and the programming of the instrument method was guided by the  protocols detailed in 
  52 
the product manual [59]. Mobile Phase A was prepared with 50 mM sodium phosphate and 
150 nM of sodium chloride dissolved in one liter of MilliQ water and pH-adjusted to 7.5 
with concentrated HCl. Mobile Phase B was prepared the same way, but a greater amount 
of HCl was added to adjust the pH to 2.5. A solvent wash of 90% Mobile Phase A and 10% 
acetonitrile used, and an additional solution of Mobile Phase A with 0.1% sodium azide 
was prepared for column storage. A constant flow rate of 0.5 mL/min at a detection wave-
length of 218 nm was employed for 8 minutes per sample, with a 3 minute equilibration 
period in between samples. Serial dilutions of a Protein A standard were prepared for the 
generation of a calibration curve, and samples were run immediately thereafter. Antibody 
concentrations were calculated by integrating the chromatogram peaks and mathematically 
relating them to the calibration data. Specific productivity was calculated by subtracting 
the difference in concentration between each consecutive pair of samples and dividing by 
the number of viable cells. 
 
4.3.7 HPLC Quantification of Amino Acids in Spent Media 
To quantify the concentration of each of the 20 amino acids found in mammalian cells, an 
HPLC protocol was developed based on methods published by Agilent Technologies, the 
manufacturer for the Zorbax C18 column that was used [60]. Two mobile phases were 
prepared: the first was a mixture of 10 mM sodium phosphate, 10 mM sodium tetraborate, 
and 0.5 mM sodium azide pH-adjusted to 8.2, and the second was a mixture of 45% ace-
tonitrile, 45% methanol, and 10% MilliQ water by volume. A constant flow rate of 1.5 
mL/min was chosen because it minimized sample run time while maintaining clear sepa-
ration of peaks. Two UV-Vis wavelengths were measured simultaneously during analysis: 
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338 nm (which was able to capture every amino acid except for proline), and 262 (opti-
mized for the maximum absorption of proline). Calibration standards were prepared by 
supplementing a purchased standard mixture of pure amino acids with any that were not 
originally included by the retailer. Dilutions of these standards were run not only for the 
generation of a calibration curve but also for the identification of retention times for each 
amino acid. The methods published by Agilent provided a point of reference for me to 
conclude which peaks corresponded each amino acid, which allowed me to define a peak 
window within Chromeleon for each one; this essentially communicates the expected re-
tention time for every amino acid (with some room for error) such that it can automatically 
perform peak identification for each one of the 40 samples run. Identified peaks were inte-
grated by Chromeleon, and the calibration data was used to determine the concentration of 
each respective amino acid per sample.  
Table 4.1: Amino Acid Specifications for HPLC Analysis 
Peak Window # Amino Acid Name Retention Time (min) 
Max Absorbance 
Wavelength (nm) 
1 Aspartate (Asp) 1.740 338 
2 Glutamate (Glu) 2.797 338 
3 Asparagine (Asn) 5.040 338 
4 Serine (Ser) 5.357 338 
5 Glutamine (Gln) 6.100 338 
6 Histidine (His) 6.353 338 
7 Glycine (Gly) 6.703 338 
8 Threonine (Thr) 6.920 338 
9 Arginine (Arg)  8.037 338 
10 Alanine (Ala) 8.300 338 
11 Tyrosine (Tyr) 9.690 338 
12 Cysteine (Cys) 10.943 338 
13 Valine (Val) 11.757 338 
14 Methionine (Met) 12.017 338 
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Table 4.1: Amino Acid Specifications for HPLC Analysis (Continued) 
15 Tryptophan (Trp) 12.957 338 
16 Phenylalanine (Phe) 
13.390 338 
17 Isoleucine (Ile) 13.603 338 
18 Leucine (Leu) 14.303 338 
19 Lysine (Lys) 14.713 338 
20 Proline (Pro) 18.998 262 
 
4.3.8 HPLC Quantification of Vitamins in Spent Media 
The method utilized for vitamins quantification was designed around one that was pub-
lished by Thermo Fisher Scientific for the simultaneous quantification of water and fat 
soluble vitamins [61]. For the purposes of this research, however, only eleven water-solu-
ble vitamins were investigated – their retention times and maximum detection UV-Vis 
wavelengths are displayed in Table 4.2. Using the Thermo Fisher protocol as guidance, 
peak identification was carried out by running pure samples of each individual vitamin to 
determine the retention times relative to one another, as well as their optimal detection 
wavelengths. Serial dilutions of a mixture of all eleven vitamins were also prepared to 
obtain calibration data. Despite there being a substantial amount of heterogeneity in the 
optimal detection wavelengths for the vitamins communicated by Thermo Fisher, it was 
empirically determined here that just three wavelengths were sufficient to capture the 
peaks.  
Table 4.2: Vitamin Specifications for HPLC Analysis 
Vitamin Name Retention Time (min) Max Absorbance Wavelength (nm) 
Thiamine (B1) 1.806 260 
Table 4.2: Vitamin Specifications for HPLC Analysis (Continued) 
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Ascorbic Acid (C) 2.316 200 







Nicotinamide (B6) 4.838 260 
Pantothenic Acid (B5) 6.293 200 
Folic Acid (B9) 9.247 200 
Cyanocobalamin (B12) 9.396 200 
Riboflavin (B2) 10.154 290 
Biotin (B7) 10.256 200 
 
4.3.9 Quantification of Metabolites in Spent Media 
The extracellular concentrations of lactate, glucose and ammonia were measured using a 
benchtop BioProfile Flex 2 from Nova Biomedical. This technique was much simpler than 
HPLC and required no additional preparation of solutions. The machine was calibrated 
beforehand using the built-in software command, and Quality Control (QC) levels 1-5 from 
Nova Biomedical were run to ensure measurement accuracy.  
 
4.3.10 Statistical Analysis 
The results in this chapter depict the mean value for each data point across the four replicate 
flasks, and the error bars depict the standard deviation for each mean. The means and stand-
ard deviations were calculated using the AVERAGE() and STDEV() functions in Excel, 
respectively. Brackets with a single asterisk signify clusters of data points that are not sig-
nificantly different from one another, as determined by single-factor ANOVA tests con-
ducted in Excel (p < 0.05). 
4.4 Results 
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4.4.1 Viable Cell Density and ATP per Viable Cell 
Figure 4.1 visualizes the viable cell density and ATP per viable cell for each of the four 
batch cultures. The maximum observed cell density was slightly greater than 7 x 106 
cells/mL and the culture longevity was 10 days (240 hours). There is very low growth 
during the first 24 hours, indicating the lag phase. This was followed by an exponential 
growth phase between 24 and 96 hours and a sudden onset of stationary growth at 96 hours, 




Figure 4.1: Viable Cell Density and ATP Per Cell for GS-CHO Batch Cultures 
 
ATP levels were not significantly different during the first 48 hours, but there was a clear 
and sudden decline at 72 hours. A steady decline in ATP availability per viable cell was 
observed for nearly every sequential day following 72 hours, indicating consistently de-
clining ATP availability. 
 

























  57 
Figure 4.2. visualizes the HPLC mAb chromatographs of days 0 and 10 for one flask, 
showing clearly the production of the antibody by day 10. Differences in concentration 
between each consecutive pair of samples was calculated and normalized per viable cell to 
show that specific productivity decreased over time in Figure 4.3. The production of mAb 
per viable cell did not significantly change during cellular growth but suddenly and pro-
gressively declined during the stationary phase and subsequent death. 
 
 
Figure 4.2: HPLC Quantification of mAb Production in Supernatant Samples 
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Figure 4.3: mAb Concentration and Production in Supernatant Samples 
 
4.4.3 HPLC Quantification of Amino Acids 
Examples of two amino acids HPLC chromatographs of samples taken at day 0 and day 10 
for one flask are shown in Figure 4.4 below, visualizing the depletion of select amino acids 
(such as glutamate, aspartate and asparagine) over the course of the culture. The concen-
tration profiles for key amino acids will be shown and discussed in Chapter 5 within the 
context of the multivariate analysis. Glutamine, glycine, and alanine (peaks 5, 7 and 10) 
are not present in the supernatant at the start of the culture because they are initially pro-
duced rather than consumed by the cells and are therefore not included in the basal media 
composition. The amino acids which correspond to the peak windows listed along the top 
of each chromatograph are given in Table 4.1, and peaks are also labeled by amino acid 
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Figure 4.4: HPLC Quantification of Amino Acids in Spent Media (Day 0 and Day 10) 
 
4.4.4 HPLC Quantification of Water-Soluble Vitamins 
The chromatographs for days 0 and 10 for one flask are shown in Figure 4.5. All five col-
lected wavelengths are overlaid, but the automatic peak identification based on the defined 
windows can only be applied to a single wavelength, therefore the vitamins quantified at 
200 nm are showed only (the retention times and respective detection wavelengths for the 
remaining vitamins are identified in table 4.2). 
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Figure 4.5: HPLC Quantification of Vitamins in Spent Media (Day 0 and Day 10) 
 
4.4.5 Glucose, Lactate, and Ammonia Consumption and Production 
Graphs of specific lactate and ammonia production are depicted in Figure 4.6 below their 
respective graphs of extracellular concentrations, since these metabolites were primarily 
produced. Glucose, however, was exclusively consumed, so a graph of specific consump-
tion was chosen instead. Glucose was steadily depleted until 192 hours, when the extracel-
lular concentration reached approximately 0 mM. Ammonia, a common byproduct of 
amino acid metabolism, steadily accumulated except for a temporary stall in production 
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between 96 and 144 hours. This shift correlated strongly with the decrease in specific pro-
duction of lactate that preceded its eventual consumption. In general, it can be seen that the 
specific consumption and production of these metabolites was highest during the lag and 
exponential phases and stabilized at lower magnitudes during the stationary phase.  
 
 
Figure 4.6: Extracellular Concentrations and Consumption/Production of Metabolites 
 
4.5 Discussion 
4.5.1 Growth, Viability and mAb Productivity 
The observed growth and viability trends for these cultures were as expected – a brief lag 
in growth during the first 24 hours, followed by very clearly defined growth, stationary and 
death phases. The consistently declining availability of ATP per cell was also predictable, 
given that the cells were not fed any supplemental nutrients during the culture to produce 
increased amounts of ATP.  The mAb productivity was rather low at a maximum titer of 
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under 100 mg/L, and one possible reason for this is the multiple occurrences of liquid ni-
trogen exhaustion in our cryopreservation tank (presumably due to a leak) which resulted 
in compromised viability of the existing vials. The productivity of the recovered cells may 
have been affected by these incidents, but it is also possible that these cells did not originate 
from a very productive clone to begin with. Regardless, the low productivity of the cells 
may not be generally ideal but is acceptable for the purposes of these experiments because 
it theoretically leaves more room for future optimization. 
 
4.5.2 HPLC Quantification of Amino Acids and Water-Soluble Vitamins 
The method for HPLC quantification of amino acids was robust and successful, and the 
key results from the analysis will be shown and discussed in greater detail in the following 
chapter. Unfortunately, the vitamins method was overall less robust than the amino acids 
quantification method, as the baseline was unstable in certain segments and the resolution 
of some peaks was very poor (as can be seen in Figure 4.5). This resulted in the need for 
manual integration when peaks were unable to be correctly identified by Chromeleon. This 
inevitably establishes some potential for error in the calculations for concentration, so there 
is somewhat less confidence in the accuracy of these results compared to the amino acid 
concentrations. Future changes will need to be explored in the optimization of this protocol, 
such as alternative mobile phases, phase gradients, flow rates and sample preparation. 
 
4.5.3 Glucose, Lactate and Ammonia 
The trends observed for glucose, lactate and ammonia in the BioProfile analysis depicted 
in Figure 4.6 are typical for mammalian cell culture – a halt in the accumulation of lactate 
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can be seen just before the onset of stationary growth, and this shift is documented very 
extensively in the literature (although still not fully understood) [62]. A corresponding de-
crease in the specific consumption of glucose is also observed alongside this shift due to 
an increased dependence on anaplerotic pathways in the TCA cycle. These findings will 
be juxtaposed alongside the profiles for key amino acids in Chapter 5 where the clusters 
and shifts identified in the multivariate analysis will be explored in close detail to hypoth-
esize causational relationships between the depletion and production of metabolites and 
growth behavior.
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CHAPTER 5 
 





An understanding of energy metabolism in mammalian cells is critical for the optimization 
of media composition. Culture media provides extracellular nutrients such as amino acids, 
glucose, lipids, vitamins, inorganic salts and trace metals which are necessary to support 
metabolic processes for cell survival, growth and proliferation, biomass composition, and 
recombinant protein/antibody production [34]. Vitamins cannot be endogenously produced 
but play important roles as enzyme cofactors and as antioxidants in redox metabolism (as 
do some trace metals) [41], [42]. Lipids are important for plasma membrane composition 
and lipid metabolism, and amino acids and glucose significantly contribute to energy pro-
duction. Glucose is a 6-carbon sugar that is broken down in the cytosol into two 3-carbon 
molecules of pyruvate in an aerobic process known as glycolysis, which simultaneously 
produces two ATP and NADH molecules each from the reduction of NAD+, shown at the 
top of Figure 5.1.  
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Figure 5.1 High-Level Overview of Energy Metabolism (used with permission from [65]) 
 
Pyruvate can then be anaerobically metabolized to oxidize NADH into NAD+ (for the con-
tinuation of glycolysis), which produces the toxic metabolite lactate in a process known as 
lactic acid fermentation. Alternatively, in the presence of enough oxygen, pyruvate is in-
stead converted into acetyl-CoA by pyruvate dehydrogenase (PDH) as the first step in the 
tricarboxylic acid (TCA) cycle. The TCA cycle is an aerobic alternative to lactic acid fer-
mentation that takes place in the mitochondria and generates one GTP, three NADH, one 
FADH2 and two CO2 molecules in a single cycle. It involves many intermediates, as shown 
in Figure 5.1, which can be synthesized from free amino acids by transaminase enzymes; 
these alternative synthesis routes are formally referred to as anaplerotic pathways, and their 
existence dictates a significant necessity for amino acid availability in media composition. 
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Additionally, it should be noted that these pathways contribute substantially to ammonia 
production and accumulation, as can be seen in the reactions for glutamine and asparagine 
conversion into glutamate and aspartate, respectfully (as well as many others not explicitly 
shown in the figure). A summary of the amino acids involved in anaplerotic pathways for 
the TCA cycle is given in Table 5.1, adapted from findings reported in a biochemistry 
textbook published in 2020 [66]. 
 
Table 5.1: Anaplerotic Pathways for TCA Cycle Precursors and Intermediates [66] 
Amino Acid Precursors TCA Cycle Precursors/Intermediates 
Glycine à Serine 
Methionine à Cysteine 
Tryptophan à Alanine 
Pyruvate 






Arginine à Glutamate 
Proline à Glutamate 
Histidine à Glutamate 







Asparagine à Aspartate 
Phenylalanine à Tyrosine Fumarate 
Asparagine à Aspartate Oxaloacetate 
 
The electron-carrying coenzymes produced by the TCA cycle, NADH and FADH2, then 
proceed to the electron transport chain where they undergo a series of redox reactions to 
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generate a significantly greater amount of ATP than with glycolysis alone. Upregulated 
TCA cycle activity is, however, associated with redox stress and increased generation of 
reactive oxygen species (ROS), which must be neutralized by antioxidant molecules. The 
shifting dependencies on and away from lactic acid fermentation and the TCA cycle 
throughout mammalian cell culture, and the metabolic behaviors that characterize such ac-
tivity, are a significant research area for ongoing studies. These principles of energy me-
tabolism are important to understand as a basis for drawing conclusions from the data col-
lected in the GS-CHO cultures. 
 
5.2 Aims and Objectives 
The aim of this chapter is to apply the multivariate analysis platform previously established 
to conglomerate the data and profile cellular behavior at a high level. Once significant 
shifts and clusters of similarity are identified, knowledge of energy metabolism will be 
used to form hypotheses on the shifting metabolic behavior of the cultures and identify 
areas in need of optimization. From the metabolic profiles data, specific consumption will 
be calculated to analyze metabolic behavior from a different perspective. Given the com-
pounded error from the specific consumption calculations (standard deviations in both vi-
able cell density and the metabolite consumption), single-factor ANOVA will be per-
formed to elucidate only truly significant shifts in consumption patterns for each variable 
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5.3 Materials and Methods 
5.3.1 Creation of an Excel Template File for Data Consolidation 
To streamline the data input process and ensure accurate reproducibility, an Excel template 
file was created with the proper formatting to allow for simple copying and pasting from 
instrument reports. The export formatting of each instrument report, as well as the retention 
times of everything being measured (in the case of HPLC) was used to guide the formatting 
of the Excel template to maximize ease of use. The template was designed such that raw 
data from each report would be converted to units of mM (if necessary), averaged across 
replicates for the calculation of mean and standard deviation, and graphs for each data 
component would be automatically populated with pre-formatted axis labels and standard 
deviation bars. Different graphs and calculations for different analyses were segregated by 
sheet, and all final data was consolidated into a separate sheet which could be exported in 
.CSV file format for multivariate analysis in R. The dataset analyzed was composed of 11 
averaged observations of 40 independent variables: all 20 amino acids (mM), 11 water 
soluble vitamins (mM), glucose (mM), lactate (mM), ammonia (mM), ATP per cell 
(mmol/cell), mAb titer (mg/L), and viable/apoptotic/dead/total cell densities (cells/L).  
 
5.3.2 Multivariate Analysis 
The HCA and PCA were conducted using the same R code and data processing as in Chap-
ter 3, and the same correlation between culture growth stages and identified clusters is 
applied. Both vertical and horizontal dendrograms are applied to the HCA heatmaps for 
clustering analysis, but the vertical clustering is removed in additional figures to ensure 
temporal ordering of data points, which improves visual clarity of metabolic shifts. 
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5.3.3 Statistical Analysis 
In addition to the mean and standard deviation calculations for the metabolite profiles per-
formed previously, additional single-factor ANOVA tests were applied to the calculated 
specific consumption data. These ANOVA tests were performed using Excel macros which 
automatically executed the single-factor ANOVA function in the Analysis Toolpak against 
sequential pairs of data (for example: 0-24 and 24-48 hours, 24-48 and 48-72 hours, etc.). 
The specific consumption between two pairs of data was deemed to be significantly differ-
ent only if p < 0.01 in order to highlight only the most significant metabolic shifts for clarity 
of visualization. Insignificantly different clusters of data were averaged using the mean of 
all values in the cluster and the values for each data point within clusters was replaced by 
their respective average. A new .csv file was created in Excel to reflect these changes and 
subsequently analyzed in R for HCA and PCA.  
 
5.4 Results 
5.4.1 Hierarchical Clustering Analysis of Concentration Profiles 
The HCA performed on extracellular concentration profiles is shown in Figure 5.2.  Data 
were standardized using the z-scoring methodology previously described. It can once again 
be seen that each of the four stages of growth exhibits a unique metabolic profile, as shown 
by the unsupervised formation of four clusters in Figure 5.2 which have a strong correlation 
with the time points for each growth phase seen in the viable cell density graph (Figure 
4.1). 
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Figure 5.2 HCA of GS-CHO Batch Culture 
 
Additionally, a high-level view of the metabolic shifts can be seen – particularly from ex-
ponential to stationary phase. It is at this point that a majority of vitamins and amino acids 
Lag Exp. Stationary Death 
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exhibit a significantly lower extracellular concentration compared to the population mean 
(as indicated by the sudden shift from red to blue). The bottom quarter of the heatmap 
shows the cluster of variables that yielded an increased concentration over time, namely 
toxic metabolites (lactate, ammonia), mAb titer, dead/apoptotic cells, and a few amino ac-
ids (threonine, glycine and alanine). Vertically, the profile of viable cell density is clustered 
the closest with lactate because the initial shift away from lactate production correlates 
exactly with the onset of the stationary growth phase, and the rapid decline in viable cell 
density coincides with significant lactate consumption. In terms of amino acids that were 
observed to accumulate in the supernatant, glycine was steadily produced throughout the 
time course of the culture and there was a notable shift from production to consumption of 
alanine at 144 hours. While threonine production was observed in the HCA, further inspec-
tion of its concentration profile led to the conclusion that the actual increase was not very 
significant when accounting for standard deviation, and the overall variation in its concen-
tration was small in magnitude, so this was not explored further. The graphs of concentra-
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Glutamine appears to exhibit consistent production until 96-120 hours, after which it 
experiences consumption. This shift was observed to immediately follow the exhaustion of 
glutamate at 120 hours. Directly following the exhaustion of glutamine at 144 hours, it can 
be seen that alanine shifted away from production immediately towards consumption. 
Following glutamate exhaustion, it was observed that ammonia production began once 
again following a brief period of consumption between 96 and 120 hours. A graph of this 
relationship is depicted below in Figure 5.4: 
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Aspartate was clustered most closely with glutamate in the HCA, and upon closer inspec-
tion, it was discovered that this was because it too was completely exhausted by 120 hours. 
The concentration profiles of aspartate and asparagine, which are related through their re-
lationship with oxaloacetate in the TCA cycle, are shown in Figure 5.5 below; both are 
nearly fully exhausted by 120 hours. 
 
 
Figure 5.5: Extracellular Aspartate and Asparagine Exhaustion 
 
Valine, arginine, phenylalanine and histidine exhibited slightly higher extracellular con-
centrations at 192 hours compared to the neighboring time points in the HCA, but upon 
further inspection of their independently graphed profiles, these changes were not very 
significant statistically nor were they of notably high magnitude. Therefore, this observa-
tion was not investigated further. 
        All vitamins were consumed in culture to an extent; of those measured, pantothenic 
acid conveyed the most striking change in consumption pattern. A steady concentration 
was observed up until 216 hours when a sharp drop was discernable, and despite insignif-
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at 216 hours. Pyridoxal, another vitamin in the B6 family with functionally similar signifi-
cance to pyridoxine, was exhausted around 96 hours – differing greatly from the pattern 
observed for pyridoxine. Most remaining vitamins showed shifts in consumption that co-
incide with the onset of the stationary growth phase at 96 hours and the relatively decreased 
metabolic activity associated with it. The concentration profiles for pyridoxal, pyridoxine 
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5.4.2 Principal Component Analysis of Concentration Profiles 
PCA was performed on the data and visualized in Figure 5.7. The first principal component 
accounts for a staggering 73.47% of the total variation, and PC2 is far less significant at 
11.82%. The distinct metabolic profile of each growth phase can be seen by the clearly 
separated clusters of data points, color-coded to coordinate with their respective previously 
identified HCA cluster. The first two data points are spatially proximal, indicating smaller 
change in extracellular concentrations likely as a result of initial low cell density. As the 
cells enter exponential growth, it can be seen that metabolic activity is high as the concen-
tration profiles change significantly during each sample interval. After the onset of the 
stationary phase at 96 hours, the metabolic changes are less significant because viable cell 
density is maintained at steady state. The last two data points are significantly separated 
from the other clusters, representing the rapid cell death observed during this point in the 
culture. 
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Figure 5.7: PCA of GS-CHO Batch Culture 
 
5.4.3 Multivariate Analysis of Specific Consumption and Production of Nutrients 
After comprehensive analysis of the spent media profiles, specific production and con-
sumption were calculated for each variable and analyzed multivariately. Calculations were 
performed by dividing the difference in extracellular concentration (mM, or mmol/L) be-
tween two consecutive data points by the viable cell density (cells/L) recorded at the time 
of the later datapoint, resulting in a final value of mmol/cell. Positive values indicate net 
consumption per cell during that interval of time, and negative values indicate net produc-
tion per cell. This data, however, was not utilized in the multivariate analysis because it 
was too difficult to discern significant relationships. In order to visualize more meaningful 
results, a single-factor ANOVA test was run for each consecutive pair of values to identify 
significant shifts within the data (p < 0.01). Clusters of values for each measured variable 
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that were statistically insignificant from one another between sequential time points were 
averaged such that all data points within the cluster would exhibit the same value in the 
HCA heatmap. The resulting HCA and PCA are shown in Figures 5.8 and 5.9, and have 
substantially enhanced clarity due to the elucidation of significant variation only.  
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Figure 5.8: HCA of GS-CHO Specific Consumption Data in Batch Culture 
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Figure 5.9: PCA of GS-CHO Specific Consumption Data in Batch Culture 
 
        Immediately, the differences between the specific consumption data and the previ-
ously presented extracellular concentration data are visually obvious. There is a large block 
of the HCA heatmap which is purely gray, indicating no significant variation (p < 0.01) 
within the entire rows (according to single-factor ANOVA considering all groups). All 
members of this block are amino acids that were not identified as significant in the prior 
analysis, so it was concluded that these were not limiting nutrients for the cultures. Another 
key difference between the HCA for specific consumption and extracellular profiles is the 
vertical clustering, because the four most significant clusters no longer correlate perfectly 
with the four stages of culture growth; instead, there is a segmentation of the exponential 
phase at 72 hours and a distinct cluster between 72 and 120 hours which encompasses the 
transition from late exponential into stationary. All time intervals after 120 hours are 
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clustered together, with the interval from 216-240 hours (first interval of rapid cell death) 
being a standout datapoint within the cluster. From the PCA in Figure 5.9, a clear divide 
can be drawn distinguishing data points before 120 hours and those taken after 120 hours. 
The first five days of the culture are characterized by very dynamic specific consumption 
behavior, suggesting a constantly evolving metabolic state prior to 120 hours. After 120 
hours, the specific consumption of media components appears to insignificantly change, as 
indicated by the comparatively much tighter cluster. In order to better visualize dynamic 
specific consumption in chronological order, another heatmap was generated without the 
inclusion of column clustering to allow for the temporally sequential ordering of data 
points, shown in Figure 5.10. 
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Figure 5.10: HCA of GS-CHO Specific Consumption Data (no column clustering) 
 
A high-level observation that can be made from the heatmap is that a majority of the nutri-
ents exhibit heightened specific consumption during the first 48-72 hours (before late-stage 
exponential growth). Given the established significance of 120 hours as a point of meta-
bolic shift, as seen in the HCA and particularly PCA, focus was placed on changes that 
occurred shortly before and after then. It is known from the extracellular profile data that 
glutamate was completely exhausted at 120 hours, and this is also confirmed by the specific 
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consumption data as indicated by the dark red square (high consumption) between 96 and 
120 hours. It can also clearly be seen that high specific consumption of glutamine between 
120 and 144 hours follows glutamate exhaustion, and an immediate shift from consistent 
production to consistent consumption of alanine follows glutamine exhaustion at 144 
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The relationship between glutamate and aspartate consumption is also elucidated more 
clearly than before, as there is a sudden onset of specific consumption during late-stage 
exponential growth (72-96 hours) carrying over into early stationary growth, until their 
mutual exhaustion at 120 hours. Asparagine, the anaplerotic precursor to aspartate, is con-





Figure 5.12: Specific Consumption of Aspartate and Asparagine 
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The sudden consumption of pantothenic acid and pyridoxine between 192 and 216 hours, 
which was noted previously, is emphasized more greatly here. Interestingly, this instanta-
neous consumption is not sustained after the 24-hour interval that it is observed. Similarly, 
biotin exhibited high specific consumption that was only observed between 24 and 48 
hours, followed by a rapid decrease in specific consumption. The specific consumption 















Figure 5.13: Specific Consumption of Pantothenic Acid, Pyridoxine and Biotin 
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5.5 Discussion 
5.5.1 Glycine Production and the Alanine Shift 
Glycine production is hypothesized to be a result of serine hydroxymethyltransferase 
(SHMT) activity, an enzyme which catalyzes the interconversion of serine (which was 
steadily consumed) into glycine. The precise reason for this activity is yet to be fully un-
derstood, but both amino acids are known to be involved in nucleotide biosynthesis, so it 
is possible that this GS-CHO clone has a preferential need for glycine over serine [67]. The 
alanine shift is likely a result of the metabolic shifts surrounding energy metabolism; ala-
nine can be used for the direct synthesis of pyruvate, which the cells may resort to in the 
instance that glucose has been substantially depleted and glycolysis is no longer a reliable 
source of pyruvate production [62]. Of the amino acids depicted in Figure 5.3, which clus-
tered similarly in the HCA based on their production patterns, the metabolic shift for 
alanine was concluded to be the most interesting and significant. Its strong role in energy 
metabolism led to the investigation of other amino acids or vitamins with possibly related 
significant shifts.  
 
5.5.2 Glutamine Shift and Glutamate Exhaustion 
The glutamine shift from production to consumption at 120 hours occurs just 25 hours prior 
to the Alanine shift and can be explained by one of the key anaplerotic reactions of the 
TCA cycle which involves the biosynthesis of glutamate from glutamine for the ultimate 
conversion into a-ketoglutarate, a TCA cycle intermediate; once the cells have exhausted 
their free supply of extracellular glutamate, it must be endogenously produced to maintain 
the TCA cycle [68]. The exhaustion of glutamine at 144 hours coincides with the alanine 
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shift, which is sensible because of the roles they play in energy metabolism; the exhaustion 
of both glutamine and glutamate severely limits α-ketoglutarate as a viable entry point into 
the TCA cycle, so the cells shift towards alanine consumption for the purpose of pyruvate 
generation. The temporary halt in ammonia production between 96 and 120 hours is 
possibly a result of ammonia being a byproduct of the transaminase reactions for glutamine 
and alanine conversion into glutamate and pyruvate respectfully. 
 
5.5.3 Asparagine and Aspartate Exhaustion 
Asparagine and aspartate are two other amino acids that were observed to be completely 
exhausted. Aspartate is a critical nutrient because it is the only known free amino acid that 
can be used for the anaplerotic synthesis of oxaloacetate, the final product of the TCA 
cycle, making it functionally comparable to the relationship between glutamate and ke-
toglutarate [66]. However, while glutamate can be synthesized from numerous other free 
amino acids, aspartate can only be synthesized from asparagine, which was observed to be 
exhausted at 120 hours simultaneously with aspartate. This too was a likely trigger for the 
shift towards alanine consumption at 144 hours, because at that point, the oxaloacetate 
could only be produced from malate within the TCA cycle, or from pyruvate directly (cat-
alyzed by pyruvate carboxylase) [66]. 
 
5.5.4 Supernatant Concentrations of Pantothenic Acid, Pyridoxal and Pyridoxine 
Pantothenic acid is required for the synthesis of coenzyme A (CoA), which plays a key role 
in both lipid metabolism and the TCA cycle, with the formation of acetyl-CoA and suc-
cinyl-CoA [69]. Referring back to the graph of viable cell density in Figure 4.1, it can be 
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seen that the number of viable cells was in rapid decline at 216 hours, and it must also be 
noted that glucose concentration was almost entirely depleted just 24 hours prior to this. 
Therefore, it is hypothesized that the complete exhaustion of extracellular glucose 
prompted a stark shift in cellular dependency on the TCA cycle for energy production, and 
therefore suddenly increased cellular demand for pantothenic acid. Additionally, the con-
centration of pyridoxine also yielded a somewhat sudden decrease at 216 hours, albeit to a 
lesser extent. Pyridoxine is an important cofactor in many catabolic and biosynthetic reac-
tions for amino acid metabolism, making it similarly important for energy generation and 
related to TCA cycle upregulation; it is also capable of neutralizing ROS, so its relationship 
to TCA cycle activity and redox stress is clear [63]. The exhaustion of pyridoxal around 72 
hours is sensible, because pyridoxine has been reported to be the most biologically active 
member of the B6 family, explaining initial cellular preference for it over pyridoxal [69]. 
 
5.5.5 Relating the PCA to the HCA 
It is not surprising that a majority of the variation can be captured by a single principal 
component in the PCA because by looking at the HCA heatmap in Figure 5.2, it can clearly 
be seen that a majority of the variables exhibit significantly similar concentration profiles, 
characterized largely by high concentrations during the lag and exponential phases, fol-
lowed by lower concentrations and consumption during the stationary phase. Therefore, 
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5.5.6 Calculation of Specific Consumption and Production 
The specific consumption and production profiles were in many cases quite different from 
the patterns observed in the extracellular concentration profiles. While it may initially seem 
as if these calculations would yield similar results to the extracellular concentration profiles 
alone, the reality is that it can actually be quite transformative. Much like calculating a 
derivative, it shifts the focus from the magnitude of the values themselves to the magnitude 
of change between them. Additionally, the normalization to viable cell number at a specific 
point in time elucidates metabolic activity that may not be clear during time points of lower 
cell density, such as the lag phase. A prime example of this is the specific production of 
mAb (Figure 4.2) – the graph of extracellular mAb concentration suggests that mAb pro-
duction is low during the lag phase, but the graph of specific production communicates the 
opposite. When accounting for the lower cell density, it can be seen that productivity was 
consistently at its highest during the first four days of the culture and decreased in steady 
increments until reaching its low at 216 hours, the first observation of rapid cell death. This 
is contradictory to some works that have been published, which show that upregulated TCA 
cycle activity associated with the stationary phase of CHO cultures correlated positively 
with productivity in fed-batch cultures [70]. This was hypothesized to be a result of the 
comparatively efficient energy metabolism of the TCA cycle and lactate consumption com-
pared to high glycolytic flux and lactate production. The likely causation for the differences 
observed between the data shared here and published findings is the application of fed-
batch culture instead of batch. The steady feeding of key nutrients, such as glutamate 
(which was comparatively exhausted near the beginning of the stationary phase in the cul-
tures described in this thesis) allows for more efficient metabolic activity that is less reliant 
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on anaplerotic pathways which accumulate ammonia, increasing the toxicity of the envi-
ronment and limiting the free amino acid availability for mAb construction. A greater avail-
ability of key nutrients for energy metabolism allows for the employment of more free 
amino acids for mAb construction rather than biosynthesis of depleted amino acids, trans-
lating to enhanced specific productivity and culture longevity and ultimately increasing 
mAb titer. This is a key advantage of fed-batch over batch culture, as described in the first 
chapter, and is the motivation behind the exclusive employment of fed-batch methodology 
in much of the current literature encompassing characterization and optimization of CHO-
based biologics production.  
 
5.5.7 Specific Consumption of Pantothenic Acid and Biotin 
Further research will need to be conducted in order to confidently suggest probable cause 
for the high specific consumption of pantothenic acid during the first 24 hours, as there is 
no clear explanation for this observation in the data. A clear shift in the consumption of 
biotin is observed during the first 48 hours before achieving steady-state – a complete lack 
of consumption is observed during the lag phase, followed by high consumption during the 
first 24 hours of exponential growth. Biotin, or vitamin B7, is an essential cofactor for 
multiple carboxylase enzymes, such as pyruvate and acetyl-CoA carboxylase, which play 
important roles in fatty acid synthesis [71]. Given that fatty acids are a key component of 
phospholipid membranes, it can be hypothesized that biotin is needed for the synthesis of 
lipid biomass for membrane construction during cell proliferation, which would explain its 
high necessity during exponential growth but not the lag phase. This, however, does not 
explain the rapid decrease in biotin demand after 48 hours, given that exponential growth 
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is sustained until 96 hours. Further optimization of the vitamins quantification protocol will 
need to be performed in order to be confident in these results, given the poor shape and 
resolution of many of the HPLC chromatographs. Overall, however, the ANOVA-sup-
ported multivariate analysis proved to reduce insignificant noise in the heatmap while still 
identifying all the same key shifts and clusters from the previous analysis.  
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CHAPTER 6 
 




6.1 Summary and Conclusions 
Efficient sample collection and proper experimental planning for cell culture allows for a 
multifaceted approach to data analysis to ultimately obtain a more complete characteriza-
tion. Quantitative methods for the determination of extracellular amino acids, vitamins and 
metabolites are critical to profiling the metabolic behavior of the culture and optimizing 
experimental parameters, such as culture conditions and media composition. However, it 
can be difficult to discern significant findings and correlations between variables in larger 
amounts of data without a standardized and streamlined approach for analysis. 
        In this work, GS-CHO cells were grown in batch culture, and samples were collected 
daily for measurement of viability, ATP, mAb titer, and extracellular amino acids, vitamins 
and common metabolites. The creation of a clean and robust Excel template file that was 
specifically designed to accommodate the formatting of electronic reports generated by our 
lab equipment facilitated easy data consolidation and standardized initial data processing 
and visualization. Programming in RStudio, with the help of existing free online resources, 
was used to standardize variables of differing units and magnitudes by computing their z-
score and provided a toolset to perform and visualize PCA and HCA.  
        The four stages of culture growth (lag, exponential, stationary, and decline) exhibit 
distinct metabolic characteristics, which were identified by the unsupervised clustering of 
extracellular metabolite profiles in both HCA and PCA. While the consumption and pro-
duction patterns of many nutrients and metabolites were deemed insignificant to the decline 
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of viability or mAb titer, numerous metabolic shifts with known significance were eluci-
dated, as well as a handful that may require further exploration to fully understand. 
        It is hypothesized that the exhaustion of glutamate, aspartate and asparagine after 120 
hours yielded significant metabolic consequences by limiting the synthesis of TCA cycle 
intermediates ketoglutarate and oxaloacetate, ultimately resulting in increased dependence 
on ammonia-producing anaplerotic pathways, pyruvate synthesis from alanine, and gener-
alized redox stress from upregulation of the TCA cycle. High specific consumption of glu-
cose during the first 72 hours of culture, which coincided precisely with the production of 
lactate, validated published claims that the metabolic shift away from lactic acid fermenta-
tion is not associated with glucose depletion, but rather a significant decrease in the rate of 
specific glucose consumption [62]. Understanding and characterizing the lactate shift in 
recombinant antibody-producing mammalian cells has yet to be fully complete but is es-
sential for the optimization of productivity. 
 
6.2 Future Steps 
The use of these findings to inform basal media supplementation and a feeding strategy for 
fed-batch culture is the necessary next step to optimize mAb production. It is clear that at 
a minimum, glutamate and aspartate need to be fed to the culture prior to their exhaustion 
during early stationary phase. It is also worth exploring the reasons for the high specific 
consumption of many vitamins during lag and early exponential (B1, C, B2, B3, B5, Pyri-
doxal, B12) while others exhibited suddenly high specific consumption at the start of via-
bility decline (B5, Pyridoxine). Future experiments will entail the employment of a Sarto-
rius Stedim single-use benchtop bioreactor for the fed-batch culturing of GS-CHO cells for 
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mAb production. The MVA techniques utilized in this work will be used to inform and 
validate a mathematical model designed by a postdoctoral researcher in the lab for the it-
erative optimization of media composition and feeding strategy for maximizing culture 
longevity and volumetric productivity.  
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